Ibrutinib improves survival in young people with diffuse large B-cell lymphoma
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies | Cell Death & Disease
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology
Cancers | Free Full-Text | Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma | Nature Medicine
miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication | Cell Death & Disease
JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
Ibrutinib improves diffuse large B-cell lymphoma survival - NCI
Overall survival following Richter transformation on ibrutinib by line... | Download Scientific Diagram
JCI - Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Trial results show that younger lymphoma patients respond well to ibrutinib | Center for Cancer Research
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
Treatment resistance in diffuse large B-cell lymphoma | Leukemia
NIH study revises molecular classification for most common type of lymphoma | National Institutes of Health (NIH)
PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR
JPM | Free Full-Text | Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma: Trends in Cancer
News on Diffuse Large B-Cell Lymphoma » Coping with Cancer
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
